With his Ph.D. in analytical chemistry from Virginia Tech, Charles C. Johnson brings a wealth of experience to his new role as chief science officer at Ally Biotech, a leading provider of bioactive delivery solutions for cannabinoids.
Johnson’s work on FDA regulatory compliance, product development and manufacturing, competitive market analysis, mergers and acquisitions and technical sales — as well as some experience in hemp and cannabis sectors, including industrial farming, extraction, refining, GMP production and nutraceuticals — further helps the company’s goal of adding legitimacy to the industry, specifically by taking a scientific approach to plant medicine.
Johnson’s arrival into the industry also coincides with Ally Biotech’s recent acquisition of the THC-infused soft-gel cannabis product, Chill Pill, which he plans to develop into new innovative products for the market.
Like many, Johnson transitioned into the cannabis industry after watching a family member experience side effects and setbacks from conventional medications being used to treat an illness.
“While watching my father suffer from rheumatoid arthritis and the less-than-effective conventional medical care that he received – which used long-term steroid and NSAID treatments, immunosuppressants, opioids and additional medication to treat the side effects of the primary prescriptions – I resolved myself to find a better way,” he says. “This emerging industry has provided me the opportunity to thrive in the pursuit of that better way.”